Interestingly, JAK1 or JAK2 inhibition in combination with BCR-ABL inhibitors have been shown to deplete CML LSCs in cell lines and mice models [149,150]. The gene discussed is JAK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.